2d
MedPage Today on MSNMixed Results for Therapeutic Candidates for Platinum-Resistant Ovarian CancerPromising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...
Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA ...
Researchers from Tokyo University of Science uncover cellular and molecular mechanisms underlying the antidepressant-like effects of the delta opioid receptor agonists, paving the way for its ...
Eosinophils play a crucial role in allergic responses, secreting cytokines and inflammatory mediators that exacerbate AR ...
and PI3K pathways, and that "it is well known that metformin inhibits P13K signalling directly by activating AMPK [AMP-activated protein kinase], leading to inhibition of mTOR signalling ...
The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...
Torqur AG, an innovative clinical-stage biotechnology company dedicated to advancing treatments for oncology and dermatology, ...
Everolimus (Afinitor) is a drug that blocks the mTOR protein and helps stop the growth and spread of cancer cells. PI3K inhibitors. Alpelisib (Piqray) and inavolisib (Itovebi) block a type of ...
The study evaluates the safety and efficacy of topical gel bimiralisib, a selective pan-PI3K/mTOR inhibitor, in patients with Actinic keratosis. The interim results highlight strong potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results